hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06280703 id: 18792 id: J4P-MC-IYAB type: OTHER domain: Eli Lilly and Company id: U1111-1301-8386 type: OTHER domain: Universal Trial Number id: 2023-510365-10-00 type: OTHER domain: EU Trial Number briefTitle: A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM) overallStatus: NOT_YET_RECRUITING date: 2024-05-15 date: 2025-02-17 date: 2025-02-17 date: 2024-02-28 date: 2024-03-06 name: Eli Lilly and Company class: INDUSTRY briefSummary: The main purpose of this study is to look at the amount of the study drug LY3938577 that gets into the blood stream and how long it takes the body to get rid of it. At a later stage of this study (part B and C) the blood sugar lowering effect and the duration of action of LY3938577 will be evaluated compared to Insulin Degludec.
The study will last up to approximately 5.5, 10 and 13 weeks for parts A, B, and C, respectively, including screening period. conditions: Healthy conditions: Type 1 Diabetes Mellitus studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: Parallel (Part A) and Crossover design (Part B and Part C) primaryPurpose: BASIC_SCIENCE masking: DOUBLE maskingDescription: Double-Blind (Part A) and Open-Label (Part B and Part C) whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 70 type: ESTIMATED name: LY3938577 name: Placebo name: Insulin Degludec name: Insulin Lispro measure: Part A: Number of participants with one or more Adverse Event (s) (AEs), and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration. measure: Part B: Number of participants with one or more Adverse Event (s) (AEs), and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration. measure: Part A: Number of Participants With Clinically Significant Changes in Vital Signs measure: Part B: Number of Participants With Clinically Significant Changes in Vital Signs measure: Part A: Number of Participants With Clinically Significant Changes in Safety Laboratory Parameters measure: Part B: Number of Participants With Clinically Significant Changes in Safety Laboratory Parameters measure: Part A: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3938577 measure: Part B: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3938577 measure: Part A: PK: Maximum Observed Concentration (Cmax) of LY3938577 measure: Part B: PK: Maximum Observed Concentration (Cmax) of LY3938577 measure: Part C: PK: Concentration of LY3938577 measure: Part B: Pharmacodynamic (PD): Area under the glucose infusion rate curve (GIR AUC) of LY3938577 measure: Part C: PD: Glucose infusion rate (GIR) of LY3938577 sex: ALL minimumAge: 18 Years maximumAge: 64 Years stdAges: ADULT facility: Profil Institut für Stoffwechselforschung city: Neuss state: Nordrhein-Westfalen zip: 41460 country: Germany role: CONTACT phone: +49 (0) 2131 4018 450 name: Oliver Klein role: PRINCIPAL_INVESTIGATOR lat: 51.19807 lon: 6.68504 hasResults: False
nctId: NCT06280690 id: NL83765.058.23 briefTitle: SGM-101 Tumor Targeted Fluorescence Endoscopy in Rectal Polyps With Suspected T1 Adenocarcinoma or High Grade Dysplasia acronym: SGM-T1 overallStatus: RECRUITING date: 2024-01-31 date: 2025-04-30 date: 2025-07-30 date: 2024-02-28 date: 2024-02-29 name: Leiden University Medical Center class: OTHER briefSummary: This will be the first trial investigating whether tumor targeted fluorescence is able to discriminate invasive T1 carcinoma / High grade dysplasia from Low grade dysplasia/normal tissue during endoscopic intraluminal resection. This will be done using the CEA-targeted fluorescent probe SGM-101. conditions: Colorectal Cancer conditions: Image conditions: Low Grade Dysplasia of Colon studyType: INTERVENTIONAL phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL interventionModelDescription: This is a single center prospective, non-randomized phase 2 proof of concept study, on the performance of SGM-101 to discriminate T1RC/HGD from LGD in patients that will be scheduled for endoscopic local en-bloc resection in the Leiden University Medical Centre (LUMC). primaryPurpose: DIAGNOSTIC masking: NONE count: 20 type: ESTIMATED name: SGM-101 measure: The ex-vivo NIR-fluorescence tumour to dysplasia ratio (TDR, T1RC/HGD to LGD ratio) on bread loafs (macroscopic) and pathology slides (microscopic). measure: - Ex-vivo NIR-fluorescence tumour-to-background ratio (TBR) and dysplasia-to-background ratio (DBR) (ex-vivo TDR already encountered within main objective) measure: - In-vivo TDR, TBR and DBR, as measured with the Quest spectrum laparoscope. measure: - The accuracy of SGM-101 to discriminate T1RC/HGD from LGD ex-vivo measure: -The accuracy of SGM-101 to discriminate T1RC/HGD from LGD in-vivo measure: - The correlation between in-vivo TBR/TDR and Kudo level (SM1 vs SM2/3) measure: - The agreement of resection margins status (R0 vs R1) assessed by fluorescence and histopathology. A resection margin is classified positive when there is a fluorescent hotspot visible in the wound bed or on the specimen. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Leiden University Medical Center status: RECRUITING city: Leiden zip: 2333ZA country: Netherlands name: Mats Warmerdam, Msc role: CONTACT phone: +31715298420 email: m.i.warmerdam@lumc.nl lat: 52.15833 lon: 4.49306 hasResults: False
nctId: NCT06280677 id: 2023.Aurora-Donor briefTitle: Aurora Test for ART Donor Patients (AURORA-Donor) overallStatus: RECRUITING date: 2024-02-16 date: 2025-04 date: 2025-09 date: 2024-02-28 date: 2024-02-28 name: Fertiga, Belgium class: INDUSTRY name: Fertilab name: Ferring Pharmaceuticals briefSummary: This is a randomized observational study. The main aim is to determine potential oocyte competence predictive mRNA expression profiles in the cumulus cells isolated form individual oocytes. In 2 patient cohorts: 1)GnRH Antagonist \& hr-FSH with GnRH Agonist trigger, 2) Progesterone \& hr-FSH with GnRH Agonist trigger. conditions: Infertility studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 160 type: ESTIMATED name: AURORA-Donor measure: Basic clinical donor patient and stimulation characteristics: P4 measure: Basic clinical donor patient and stimulation characteristics: E2 measure: Basic clinical donor patient and stimulation characteristics: Gonadotropin type and dose measure: Clinical evaluation: number of Follicles measure: Clinical evaluation: number of cumulus-oocyte complex measure: Clinical evaluation: Meiosis II oocytes measure: Clinical evaluation: Abnormal fertilization measure: Clinical evaluation: Normal Fertilization measure: Clinical evaluation: Day 3 embryo evaluation measure: Clinical evaluation: Day 5/6 embryo evaluation measure: Clinical evaluation: Day5/6 good quality blastocyst rate measure: Clinical evaluation: Embryo utilization measure: Expression profile: blastocyst formation measure: Biochemical pregnancy measure: Clinical pregnancy with positive fetal heartbeat measure: Expression profile: pregnancy prediction measure: Normalized messenger ribonucleic acid (mRNA) expression measure: Ongoing pregnancy rate measure: Live birth measure: Cumulative pregnancy measure: Cumulative live birth measure: Miscarriage rate sex: FEMALE minimumAge: 18 Years maximumAge: 35 Years stdAges: ADULT facility: Fertilab status: RECRUITING city: Barcelona zip: 08017 country: Spain lat: 41.38879 lon: 2.15899 hasResults: False
nctId: NCT06280664 id: IRB20-1151 briefTitle: Efficacy Of Hiatal Closure For GERD overallStatus: RECRUITING date: 2020-10-02 date: 2024-10 date: 2024-10 date: 2024-02-28 date: 2024-02-28 name: University of Chicago class: OTHER briefSummary: The purpose of this protocol is to study the efficacy of hiatal closure for early GERD disease. The study team hypothesizes that hiatal closure for early GERD disease is an efficacious treatment of GERD. conditions: Gastro Esophageal Reflux studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 40 type: ESTIMATED measure: Concentration of pH testing sex: ALL minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT facility: The University of Chicago status: RECRUITING city: Chicago state: Illinois zip: 60637 country: United States name: Carlisa Dixon role: CONTACT phone: 773-834-4337 email: cdixon520@bsd.uchicago.edu name: Leila Yazdanbakhsh role: CONTACT phone: 773-834-5087 email: leila.yazdanbakhsh@bsd.uchicago.edu lat: 41.85003 lon: -87.65005 hasResults: False
nctId: NCT06280651 id: RGP 2/348/44 id: RGP 2/348/44 type: OTHER_GRANT domain: kING kHALID UNIVERSITY briefTitle: Dietary Impacts on Oral Health in Autistic Children: A Cross-Sectional Analysis acronym: OHIDPAP-CS overallStatus: NOT_YET_RECRUITING date: 2024-03-25 date: 2024-04-30 date: 2024-05-15 date: 2024-02-28 date: 2024-03-15 name: King Khalid University class: OTHER briefSummary: The study aims to explore how dietary habits affect oral health in children with autism. By examining a cross-section of the autistic paediatric population, the research seeks to identify patterns or specific dietary preferences that may contribute to or mitigate oral health issues. This observational study does not intervene in participants' diets but observes existing habits and their oral health outcomes, aiming to provide insights that could guide better dietary recommendations and oral health practices for children with autism. conditions: Dental Caries in Children conditions: Autistic Disorder conditions: Dietary Habits studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 50 type: ESTIMATED name: dietary preferences and their implications for oral health in children with Autism Spectrum Disorder measure: Assess the association between oral hygiene and periodontal disease severity to identify potential implications of dietary preferences for oral health status sex: ALL minimumAge: 2 Years maximumAge: 12 Years stdAges: CHILD hasResults: False
nctId: NCT06280638 id: 2023-2095 briefTitle: CT-derived Virtual Stenting Optimize Coronary Revascularization (CT-COMPASS) acronym: CT-COMPASS overallStatus: NOT_YET_RECRUITING date: 2024-02 date: 2024-12 date: 2025-12 date: 2024-02-28 date: 2024-02-28 name: China National Center for Cardiovascular Diseases class: OTHER_GOV briefSummary: A considerable number of patients presented with anatomically successful PCI results still suffer from functionally unresolved ischemia, which might be the cause for over one-fourth of patients experiencing recurrent angina at 1 year or adverse events at 2 years. Currently, the post-PCI physiology measurement is one of the effective metrics to quantify residual ischemia, and a suboptimal post-PCI result is strongly associated with worse outcomes. However, PCI optimization based on post-PCI physiology is, to certain extent, a provisional rescue action for a suboptimal index procedure, which may not be fully correctable "after the fact" given selected stents, site of deployment and procedural technique.
Computed tomography (CT) coronary physiology-derived virtual stenting (CT-VS) based on pre-PCI CCTA angiograms is an augmented reality (AR) approach that simulates the post-stenting physiology assuming that the specified segment of the treated vessel is successfully dilated by implanting virtual stents. Previous studies have demonstrated the feasibility of optimizing PCI with CT-VS, with high consistency between pre-PCI simulated physiology result by CT-VS and actual post-PCI physiology results. Therefore, the application of CT-VS would help physicians to develop the best strategies while planning the procedure.
However, there is a lack of knowledge regarding the efficacy of this novel physiological index that is available pre-PCI in achieving final post-PCI optimal physiological result. The Trials of "Computed Tomography Coronary Physiology-derived Virtual Stenting Guided Revascularization Strategy in Patients with Coronary Artery Disease (CT-COMPASS)" was designed to assess the efficacy of a CT-VS vs. standard angiographic guidance in achieving post-PCI optimal physiological result (post-PCI FFR≥0.90). conditions: Percutaneous Coronary Intervention conditions: Coronary Physiology conditions: Computed Tomography studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 280 type: ESTIMATED name: Virtual stent-guided incremental optimization strategy (VIOS) name: Standard angiographic strategy measure: The proportion of patients with a final post-PCI FFR result ≥0.90 measure: The proportion of patients with final post-PCI FFR ≤0.80 measure: The rate of target vessel failure (TVF) and its component features at 6 months. measure: The rate of target vessel failure (TVF) and its component features at 1 year. measure: Change from baseline in self-reported Health-related quality of life evaluation at 6 months. measure: Change from baseline in self-reported Health-related quality of life evaluation at 1 year. measure: Change from baseline in self-reported Angina status evaluation at 6 months. measure: Change from baseline in self-reported Angina status evaluation at 1 year. measure: Procedure Duration measure: Fluoroscopy Dose measure: Contrast Material Dose sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College city: Beijing state: Beijing zip: 100037 country: China lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06280625 id: 24388 briefTitle: The Effect of the Inclusion of Soybean Flour on Glycemic Responses overallStatus: RECRUITING date: 2024-03-01 date: 2025-02-28 date: 2025-03-25 date: 2024-02-28 date: 2024-02-28 name: University of Illinois at Urbana-Champaign class: OTHER name: Kenneth Dallmier Consulting, LLC briefSummary: Foods that release glucose rapidly, leading to spikes in blood sugar and insulin (known as high glycemic index foods), generate lower satiety responses than foods with low glycemic index. High glycemic index foods are also linked to an increased risk of developing diabetes. The partial replacement of carbohydrates in rich staple foods with soy flour has the potential to reduce glycemic response and improve satiety.
In many regions of Latin America, as well as in the Middle East and North Africa (MENA) regions, bread is the staple source of calories, but it is a relatively poor source of balanced nutrition. Bread enriched with soy flour could provide higher dietary protein while moderating blood glucose (and insulin) spikes, which can help reduce insulin resistance and metabolic diseases. The results of this study could provide government and private human nutritionists with the evidence they need to formulate soy flour into bread, corn tortillas, and arepas for schools and homes. conditions: Overweight and Obesity studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: People will be evaluated with a food product prepared with different % of replacement of wheat flour for soy flour. Each person will be their own control. In other words, in randomized order, they will all be assessed with the food product prepared with the regular wheat flour (either bread, tortillas or arepas) and on two other visits with different percentages of soy flour. primaryPurpose: OTHER masking: SINGLE maskingDescription: Participants will be given the food product without information on whether it is prepared 100% with wheat flour or with different soy flour %. whoMasked: PARTICIPANT count: 30 type: ESTIMATED name: Replacement of wheat flour by soyflour measure: Plasma glucose measure: Plasma insulin measure: Hunger-Satiety sex: ALL minimumAge: 21 Years maximumAge: 45 Years stdAges: ADULT facility: University of Illinois at Urbana Champaign status: RECRUITING city: Champaign state: Illinois zip: 61820 country: United States name: Marta Y Pepino, MSc, RD role: CONTACT phone: 217-300-2374 email: ypepino@illinois.edu name: Stephanie Okoye, Pharm D role: CONTACT phone: 2173004709 email: siokoye2@illinois.edu lat: 40.11642 lon: -88.24338 hasResults: False
nctId: NCT06280612 id: RCS10042023 briefTitle: The Effect of Live Cat and Simulation Cat Therapies on Oncology Patients overallStatus: COMPLETED date: 2023-06-01 date: 2023-07-15 date: 2023-09-01 date: 2024-02-28 date: 2024-03-01 name: Karadeniz Technical University class: OTHER briefSummary: It is known that animals are good for humans physiologically and psychologically. Therefore, in this study, the effects of live cat and robotic cat therapies on the symptoms and happiness levels of oncology patients after chemotherapy were examined. conditions: Therapy-Associated Cancer conditions: Cancer Patient conditions: Happiness conditions: Symptoms studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The sample number of the research was calculated in the G\*Power 3.1.9.6 program. While α=0.05 was the error amount, 0.628 was the effect size, and 0.90 (90%) was the targeted test power, it was calculated as 36 patients for three groups (living cat group, robotic cat group, control group). Since there was no previous study on the subject, a study examining happiness levels in a different sample group was used as a reference. Considering situations such as wanting to leave the study or death during the research, each group was increased by 25%, and a total of 45 patients, 15 patients for each group, were included in the study. primaryPurpose: SUPPORTIVE_CARE masking: SINGLE maskingDescription: Since the possibility of patients being affected by each other was minimal, the study was continued with only one of the live cat groups, the simulation cat group, and the control group. For example, only the live cat group and those who received chemotherapy treatment were studied before Monday afternoon. whoMasked: PARTICIPANT count: 45 type: ACTUAL name: Pet therapy measure: Edmonton Symptom Diagnostic Scale measure: Oxford Happiness Scale Short Form sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Gümüşhane University city: Gümüşhane zip: 29600 country: Turkey lat: 40.46001 lon: 39.47176 hasResults: False
nctId: NCT06280599 id: SON KMU briefTitle: Transitional Care Model for Patients With Stroke overallStatus: RECRUITING date: 2023-09-01 date: 2024-04-01 date: 2024-04-29 date: 2024-02-28 date: 2024-04-03 name: Kaohsiung Medical University class: OTHER briefSummary: Patients with stroke benefitted from superior improvements in physical function, particularly when performing activities of daily living, fewer visits to the emergency room, less depression symptoms, and improved health-related quality of life thanks to transitional model care. Despite widespread implementation of transitional care for stroke patients, intervention effectiveness remains inconclusive, and another concern with transitional care for patients is the scarcity of effects on specific findings. conditions: Stroke studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The patients were divided into two groups: intervention (n=40) and contrast (n=40). Both groups received post-stroke usual care. The intervention group received an 8-week transitional care model for stroke patients, which included comprehensive discharge planning and home follow-up primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 80 type: ESTIMATED name: Transitional care model measure: Self-efficacy measure: Activities of daily living measure: Instrumental activities of daily living measure: Depression symptoms measure: Quality of life in stroke patients sex: ALL minimumAge: 18 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: RSUD Prof. Dr. W Z Johannes Kupang status: RECRUITING city: Kupang zip: 308 country: Indonesia name: Sakti Oktaria Batubara role: CONTACT email: oktariabatubara@gmail.com role: CONTACT phoneExt: Saragih email: itadaryanti05@gmail.com name: Ita Daryanti Saragih, Doctoral role: SUB_INVESTIGATOR lat: -10.17083 lon: 123.60694 hasResults: False
nctId: NCT06280586 id: 44/21 briefTitle: Effectiveness of Intervention in Prevention of Sarcopenia, Frailty and Functional Decline in Pre-frail Community Elderly acronym: ESPAI-F overallStatus: ACTIVE_NOT_RECRUITING date: 2021-11-15 date: 2023-10-30 date: 2024-12-31 date: 2024-02-28 date: 2024-02-28 name: Consorci Sanitari del Maresme class: OTHER briefSummary: Frailty is a geriatric syndrome characterized by a decrease in the function of various organs and systems that leads to a greater risk of suffering from diseases or disabilities. Frailty is usually accompanied by weight loss, loss of strength, slowing of walking speed, fatigue and poor physical activity. Frail people have more difficulty in carrying out the usual activities of daily life and a greater risk of needing help to be able to do them.
In the study there will be two groups, one will receive the study intervention and the other will not receive any special treatment (we call it the control group). The assignment of each individual to one group or the other will take place once you have decided to participate. This assignment will be made at random so that neither you nor your doctor can know "a priori" which group you will be in. conditions: Muscle Strengh conditions: Frailty conditions: Sarcopenia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 232 type: ACTUAL name: Multidisciplinary intervention measure: Muscle Mass measure: Muscle strength and/or Muscle function measure: Sarcopenia measure: Frailty measure: Functional Capacity 1 measure: Functional Capacity 2 measure: Functional Capacity 3 measure: Functional Capacity 4 measure: Functional Capacity 5 measure: Functional Capacity 6 sex: ALL minimumAge: 70 Years stdAges: OLDER_ADULT facility: Consorci Sanitari del Maresme city: Mataró state: Barcelona zip: 08304 country: Spain lat: 41.54211 lon: 2.4445 facility: Mateu Serra-Prat city: Mataró state: Barcelona zip: 08304 country: Spain lat: 41.54211 lon: 2.4445 hasResults: False
nctId: NCT06280573 id: MS1 briefTitle: COld Exposure With Controlled BReathing And Meditation in Patients With Multiple Sclerosis (COBRAMS) acronym: COBRAMS overallStatus: ACTIVE_NOT_RECRUITING date: 2022-09-01 date: 2025-12-01 date: 2025-12-01 date: 2024-02-28 date: 2024-03-19 name: Comenius University class: OTHER briefSummary: The goal of this interventional study is to test the effect of the anti-inflammatory and neuroprotective effects of this supplementary training program that includes breathing exercises, cold exposure, and meditation in patients diagnosed with multiple sclerosis.
Researchers will compare the effect to control groups of MS patients without intervention. conditions: Multiple Sclerosis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 50 type: ESTIMATED name: Wim Hoff method measure: concentration of pro-inflammatory cytokines measure: concentration of markers of oxidative stress measure: concentration of NfL measure: concentration of GFAP measure: concentration of ecDNA measure: Expanded Disability Status Scale measure: Timed 25-Foot Walk measure: Nine-Hole Peg Test measure: Symbol Digit Modalities Test measure: Fatigue Scale for Motor and Cognitive Functions measure: General Anxiety Disorder-7 measure: Patient Health Questionnaire-9 sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT facility: Derer's University Hospital city: Bratislava zip: 83305 country: Slovakia lat: 48.14816 lon: 17.10674 hasResults: False